By Kelly Cloonan
Shares of Merus jumped after the company posted positive interim data from a trial of its treatment for head and neck cancer.
The stock rose 31% to $54.49 on Friday. Shares have climbed 24% over the past 12 months.
The company on Thursday said data from its phase 2 trial of petosemtamab in combination with pembrolizumab showed an overall response rate of 63% and a 79% overall survival rate at 12 months for patients with head and neck squamous cell carcinoma.
The results are significantly better than for pembrolizumab alone, the control of the company's ongoing phase 3 trial, across nearly every metric, Chief Executive Bill Lundberg said.
Merus plans to share top-line interim data from one or both of its phase 3 trials in 2026, he said.
Write to Kelly Cloonan at kelly.cloonan@wsj.com
(END) Dow Jones Newswires
May 23, 2025 11:25 ET (15:25 GMT)
Copyright (c) 2025 Dow Jones & Company, Inc.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。